Comparative Pharmacology
Head-to-head clinical analysis: SERENTIL versus VESPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SERENTIL versus VESPRIN.
SERENTIL vs VESPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
Trifluoperazine is a typical antipsychotic that blocks postsynaptic D2 dopamine receptors in the mesolimbic pathway. It also has alpha-adrenergic blocking and anticholinergic effects.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
10-50 mg intramuscularly every 4-6 hours as needed; oral: 25-50 mg every 4-6 hours
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Terminal elimination half-life ranges from 1 to 2.5 hours, with a mean of approximately 1.5 hours. Due to its short half-life, multiple daily dosing is required to maintain therapeutic levels, and the drug is rapidly cleared after discontinuation.
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Primarily hepatic metabolism with metabolites excreted in urine and feces. Approximately 20-30% of a single dose is excreted unchanged in urine, with the remainder as metabolites in urine (30-40%) and feces (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic